| Clinical data | |
|---|---|
| Trade names | Oxervate |
| Other names | Recombinant human nerve growth factor; rhNGF, cenegermin-bkbj |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619001 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Ophthalmic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C583H908N166O173S8 |
| Molar mass | 13267.15 g·mol−1 |
Cenegermin, sold under the brand nameOxervate, also known asrecombinant human nerve growth factor, is arecombinant form of humannerve growth factor.[4] Cenegermin is aperipherally selectiveagonist of thetropomyosin receptor kinase A (TrkA) andlow-affinity nerve growth factor receptor (p75NTR).[4]
The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.[5]
It was approved for medical use in the European Union in July 2017,[5] and in the United States in 2018.[4][6] The USFood and Drug Administration (FDA) considers it to be afirst-in-class medication.[6]
Cenegermin isindicated for the treatment of neurotrophic keratitis.[4][5]
Cenegermin is theinternational nonproprietary name.[7] It is also known as human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced inEscherichia coli.[7]
Cenegermin is sold under the brand name Oxervate.[4][5]
